EMCDAA

(35) Report on the risk assessment of 1-(3-chlorophenyl)-2-(methylamino)propan-1-one (3-chloromethcathinone, 3-CMC) in accordance with Article 5c of Regulation (EC) No 1920/2006 (2022)

(34) Report on the risk assessment of 2-(methylamino)-1-(3-methylphenyl)propan-1-one (3-methylmethcathinone, 3-MMC) in accordance with Article 5c of Regulation (EC) No 1920/2006 (2022)

(33) Report on the risk assessment of methyl 2-{[1-(4-fluorobutyl)-1H-indole-3-carbonyl]amino}-3,3-dime- thylbutanoate (4F-MDMB-BICA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (2021)

(32) Report on the risk assessment of methyl 3,3-dimethyl-2-{[1-(pent-4-en-1-yl)-1H-indazole-3-car- bonyl]amino}butanoate (MDMB-4en-PINACA) in accordance with Article 5c of Regulation (EC) No 1920/2006 (2021)

(31) Report on the risk assessment of N,N-diethyl-2- [[4-(1-methylethoxy)phenyl]methyl]-5-nitro-1Hbenzimidazole- 1-ethanamine (isotonitazene) in accordance with Article 5c of Regulation (EC) No 1920/2006 (2020)

(30) Report on the risk assessment of 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide (methoxyacetylfentanyl) in the framework of the Council Decision on new psychoactive substances (2018)

(29) Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]cyclopropanecarboxamide (cyclopropylfentanyl) in the framework of the Council Decision on new psychoactive substances (2018)

(28) Report on the risk assessment of methyl 1-(2-phenylethyl)-4-[phenyl(propanoyl)amino]piperidine-4-carboxylate (carfentanil) in the framework of the Council Decision on new psychoactive substances (2018)

(27) Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4- yl]oxolane-2-carboxamide (THF-F) in the framework of the Council Decision on new psychoactive substances (2018)

(26) Report on the risk assessment of N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide (4F-iBF) in the framework of the Council Decision on new psychoactive substances (2018)

(25) Report on the risk assessment of methyl 2-{[1-(5-fluoropentyl)-1H-indazole-3-carbonyl]amino}-3,3-dimethylbutanoate (5F-MDMB-PINACA) in the framework of the Council Decision on new psychoactive substances (2018)

(24) Report on the risk assessment of N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (AB-CHMINACA) in the framework of the Council Decision on new psychoactive substances (2018)

(23) Report on the risk assessment of 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in the framework of the Council Decision on new psychoactive substances (2018)

(22) Report on the risk assessment of N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide (ADB-CHMINACA) in the framework of the Council Decision on new psychoactive substances (2018)

(21) Report on the risk assessment of N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]furan-2-carboxamide (furanylfentanyl) in the framework of the Council Decision on new psychoactive substances (2017)

(20) Report on the risk assessment of N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide (acryloylfentanyl) in the framework of the Council Decision on new psychoactive substances (2017)

(19) Report on the risk assessment of methyl 2-[[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]amino]-3,3-dimethylbutanoate (MDMB-CHMICA) in the framework of the Council Decision on new psychoactive substances (2017)

(18) Report on the risk assessment of 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one (α-pyrrolidinovalerophenone, α-PVP) (2016)

(17) Report on the risk assessment of MT-45 in the framework of the Council Decision on new psychoactive substances (2015)

(16) Report on the risk assessment of 4,4′-DMAR in the framework of the Council Decision on new psychoactive substances (2015)

(15) Report on the risk assessment of 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone (methoxetamine) in the framework of the Council Decision on new psychoactive substances (2014)

(14) Report on the risk assessment of 1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)pentan-1-one (MDPV) in the framework of the Council Decision on new psychoactive substances (2014)

(13) Report on the risk assessment of 3,4-dichloro-N-{[1-(dimethylamino)cyclohexyl]methyl}benzamide (AH-7921) in the framework of the Council Decision on new psychoactive substances (2014)

(12) Report on the risk assessment of 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I-NBOMe) in the framework of the Council Decision on new psychoactive substances (2014)

(11) Report on the risk assessment of 5-(2-aminopropyl)indole (5-IT) in the framework of the Council Decision on new psychoactive substances (2014)

(10) Report on the risk assessment of 4-methylamphetamine (4-MA) in the framework of the Council Decision on new psychoactive substances (2014)

(9) Report on the risk assessment of mephedrone in the framework of the Council Decision on new psychoactive substances (2011)

(8) Report on the risk assessment of BZP in the framework of the Council decision on new psychoactive substances (2009)

(7) Report on the risk assessment of TMA-2 in the framework of the joint action on new synthetic drugs (2004)

(6) Report on the risk assessment of 2C-I, 2C-T-2 and 2C-T-7 in the framework of the joint action on new synthetic drugs (2004)

(5) Report on the risk assessment of PMMA in the framework of the joint action on new synthetic drugs (2003)

(4) Report on the risk assessment of GHB in the framework of the joint action on new synthetic drugs (2002)

(3) Report on the risk assessment of ketamine in the framework of the joint action on new synthetic drugs (2002)

(2) Report on the risk assessment of 4-MTA in the framework of the joint action on new synthetic drugs (1999)

(1) Report on the risk assessment of MBDB in the framework of the joint action on new synthetic drugs (1999)

Early-warning system on new psychoactive substances — operating guidelines

Risk assessment of new psychoactive substances — operating guidelines

Guidelines for the risk assessment of new synthetic drugs